AC Immune CEO Outlines ‘Roadmap’ For Fighting Alzheimer’s
Andrea Pfeifer Outlines Her Key Points For Future AD Treatment
AC Immune’s CEO tells Scrip that treating earlier, targeting Tau, and focusing on more homogeneous populations will be needed to successfully fight Alzheimer’s Disease.
You may also be interested in...
Semorinemab met only the cognition co-primary endpoint in the Phase II LAURIET trial in mild-to-moderate Alzheimer’s patients and missed all secondary endpoints, but some firsts were achieved in the top-line readout.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Interim top-line data from CREAD 1 and 2 indicate crenezeumab is unlikely to meet its primary endpoints and the studies are being stopped, but a clinical study in Colombia in familial Alzheimer’s is set to continue.